Scientists in the US have edited the DNA of human embryos for the first time

By Catherine Sturman
It has recently been revealed that human embryos have been successfully “edited” through the use of a gene editing tool by leading US scientists. Re...

It has recently been revealed that human embryos have been successfully “edited” through the use of a gene editing tool by leading US scientists. Reported by MIT Technology Review, it will effectively eradicate diseases which could be passed down generations through the use of CRISPR technology.

The announcement has raised concerns with human rights groups regarding the ethics of such research and where it will ultimately lead, although full details have yet to be published. The use of CRISPR technology has previously been used in China, but has not previously advanced to this stage.

Successfully undertaken by US scientist Shoukhrat Mitalipov, based at Oregon Health and Science University, the use of CRISPR (clustered, regularly interspaced, short palindromic repeats), enabled scientists to edit and modify parts of DNA to prevent potential hereditary diseases. However, there are increased concerns with these methods possibly altering the process of human evolution.

The scientists used embryos sourced from fertility clinics which would not have been able to be developed further as a result of certain defects, and used donated sperm from men with hereditary diseases, in order to try and rectify these diseases through germline engineering. However, these changes would then ensure such hereditary diseases are eradicated within future generations.

The National Academy of Science previously released a report which reluctantly provided the green light for human gene editing. However, with germline editing, concerns remain surrounding the idea of “designer babies” and eugenics. Consequently, the US has forbidden any form of genetic enhancement which could alter an individual’s physical and intellectual capabilities, and blocked any potential cases where an edited IVF embryo is bought to full term, providing assurances that this research will stay in this domain entirely – for now.

 

 

Share

Featured Articles

McKinsey: Women More Likely to die of Heart Attack Than Men

McKinsey Health Institute's Lucy Pérez says cardiovascular disease top killer of women yet physicians don't know their heart attack symptoms are different

Novo Nordisk Buys $1bn Cardior in CardioVascular Move

As Novo Nordisk expands into heart medicines, we profile the Danish pharma giant who in 1923 was the first to make insulin commercially available

Shoddy Chinese Syringes Sees BD Ramp-up Production

Becton Dickinson – a major supplier of syringes – said it has upped manufacturing in its US facilities after FDA warning on China-made products

AI Tool 'Picks up Early-stage Breast Cancers Doctors Missed'

Technology & AI

AstraZeneca Buys $2bn Fusion in Next-gen Cancer Drugs Move

Medical Devices & Pharma

Eli Lilly and Amazon Pharmacy Partner on Drugs Delivery

Digital Healthcare